Items Tagged ‘Rituximab’

April 19, 2019

Mayo Clinic in the News Weekly Highlights for April 19, 2019

By Emily Blahnik Emily Blahnik (@eblahnik)

Washington Post, CTE researchers discover possible step toward diagnostic test for living patients by Jacob Bogage — Medical researchers have made what they cautiously characterized as a possible first step toward diagnosing the neurodegenerative illness chronic traumatic encephalopathy (CTE) in living patients, according to an article published Wednesday in the New England Journal of Medicine. […]

View full entry

Tags: A.L.S., aging, arthritis, Ashley Schmitt, Aspirin, Breast Cancer, burnout, cannabis, carillon, Cathy Fraser, Christie Vogel, Cris Ross


November 13, 2014

Mayo Clinic in the News Weekly Highlights

By Karl Oestreich Karl Oestreich (@KarlWOestreich)

Mayo Clinic in the News is a weekly highlights summary of major media coverage. If you would like to be added to the weekly distribution list, send a note to Laura Wuotila with this subject line: SUBSCRIBE to Mayo Clinic in the News. Thank you. Karl Oestreich, manager enterprise media relations   Today Show Allergic to Penicillin? You’re Probably […]

View full entry

Tags: 12 News Phoenix, AARP Bulletin Today, ABC News, AEDs, Albert Lea Tribune, Allergy/Immunology, Amanda Kubista, animal therapy, Argentina Star, Arizona Republic, Arizona State University, Aurora Health Care


April 18, 2014

Mayo Clinic in the News Weekly Highlights

By Karl Oestreich Karl Oestreich (@KarlWOestreich)

Mayo Clinic in the News is a weekly highlights summary of major media coverage. If you would like to be added to the weekly distribution list, send a note to Emily Blahnik with this subject line: SUBSCRIBE to Mayo Clinic in the News. Thank you. Karl Oestreich, manager enterprise media relations Star Tribune Mayo Clinic builds ‘Better’ app to […]

View full entry

Tags: ABC News, ABC15 in Arizona, About.com, acute pancreatitis, Alexa Ray Joel, allergy sufferers, Almanac, alzheimer's disease, APOE4, astigmatism, Austin Daily Herald, back pain


November 1, 2013

Mayo Clinic in the News Weekly Highlights

By Karl Oestreich Karl Oestreich (@KarlWOestreich)

    November 1, 2013 Mayo Clinic in the News is a weekly highlights summary of major media coverage. If you would like to be added to the weekly distribution list, send a note to Emily Blahnik with this subject line: SUBSCRIBE to Mayo Clinic in the News. Thank you. Karl Oestreich, manager enterprise media […]

View full entry

Tags: : ABC News Radio, AERO-News Network, Affordable care act, ANI News, Arc Minnesota, arthritis, Arthritis Today, Augusta Chronicle, autism, Aviation International News, Aynsley Smith, BEAUTFY


December 18, 2009

No Adverse Effect of Statins Seen on Lymphoma Outcomes

By Kelley Luckstein Kelley Luckstein (@KelleyLuckstein)

Statins have no effect on outcomes in patients with B-cell lymphoma treated with rituximab, but improve event-free survival in patients with follicular lymphoma regardless of rituximab treatment, according to a study published online Dec. 14 in the Journal of Clinical Oncology.   Noting that statins can block the binding of rituximab to its target, Grzegorz […]

View full entry

Tags: B-cell lymphoma, Rituximab


December 9, 2009

ASH: Drug Combo Active in Relapsed Mantle-Cell Lymphoma

By Kelley Luckstein Kelley Luckstein (@KelleyLuckstein)

Half of patients with relapsed or refractory mantle-cell lymphoma achieved major responses when treated with the investigational agent temsirolimus and rituximab (Rituxan), data from an ongoing clinical study showed. Responses persisted for almost 10 months and demonstrated durability in rituximab-refractory patients, according to Stephen M. Ansell, MD, of the Mayo Clinic in Rochester, Minn.   […]

View full entry

Tags: lymphoma, Rituximab


October 21, 2009

ACR: Rituximab Equals Standard Treatment for Vasculitis

By Kelley Luckstein Kelley Luckstein (@KelleyLuckstein)

Rituximab (Rituxan) and cyclophosphamide were equally effective in inducing remission in patients with severe ANCA-associated vasculitis, researchers reported here. After six months of treatment, 63.6% of patients randomized to receive rituximab and 53.1% of those who received cyclophosphamide achieved disease remission (P=0.089), according to Ulrich Specks, MD, of the Mayo Clinic in Rochester, Minn.   […]

View full entry

Tags: Rituximab, vasculitis


Contact Us · Privacy Policy